Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Biotech stocks, including $ALNY and $BBIO, experience significant movements following clinical trial results. $ALNY shows positive outcomes in a Phase 3 trial, leading to a surge in market cap and stock price. Analysts discuss the implications of the trial results on the biotech sector, highlighting potential treatment options for ATTR cardiomyopathy and market reactions.
$BBIO beat down by $ALNY data here Has many other assets. Might sink further but looking as an interesting potential entry at these levels. Lots of pokers in the fire. https://t.co/ba1amLukFM https://t.co/KijUyEuKxt
Today's M&A notes $FCU.to to be acquired by $PALAF for 0.1076x shares, 25.8% premium, $1.1 billion $ALIM to be acquired by $ANIP For $5.50 cash per share + CVR worth up to $0.50, 74.6% premium, $381 million $TARO / Sun Pharmaceutical deal closed https://t.co/uYyG154MKN
Monday Morning Stocks on the Move! Gainers: $ALNY, $TRNO, $UBSI, $ARGX, $RXO Losers: $INSP, $EXP, $RMD, $BBIO, $ESI #Stocks https://t.co/pls0DXRo8R
